Quantcast
Last updated on April 25, 2014 at 5:25 EDT

Latest SSM-N-8 Regulus Stories

2014-04-04 16:23:43

LA JOLLA, Calif., April 4, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, will present a company overview at the 13(th) Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 10:00 am EDT. The conference is being held at The Westin Grand Central Hotel in New York...

2014-03-05 08:28:56

- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 - LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has commenced dosing RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") in healthy volunteer subjects in a Phase I clinical study. The primary objective of the study...

2014-02-27 16:28:10

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'- LA JOLLA, Calif., Feb. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights. Corporate Strategy...

2014-02-26 16:29:07

LA JOLLA, Calif., Feb. 26, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer of Regulus, will present a company overview at the Cowen and Company 34(th) Annual Healthcare Conference on Wednesday, March 5, 2014 at 10:40 am EST. The conference is being held at the Boston...

2014-02-20 16:25:50

LA JOLLA, Calif., Feb. 20, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2013 on Thursday, February 27, 2014, after the U.S. financial markets close. Regulus will host a conference call and webcast on Thursday, February 27, 2014 at 5:00 pm...

2014-02-19 08:31:20

-RG-012 is an anti-miR Targeting microRNA-21 for the Treatment of Alport Syndrome, a Life-Threatening, Genetic Kidney Disease with No Approved Therapy- LA JOLLA, Calif., Feb. 19, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has advanced its orphan disease portfolio with the nomination of its second microRNA candidate for clinical...

2014-02-13 08:30:40

-Martin Beaulieu, Ph.D. Brings Extensive Diagnostic Assay Development Experience- LA JOLLA, Calif., Feb. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Martin Beaulieu, Ph.D. as the head of Regulus microMarkers(TM), a research and development division of Regulus designed to support the expansion of its innovative...

2014-02-04 08:34:28

-Mr. Szekeres Brings Extensive Strategic and Transactional Deal Experience- LA JOLLA, Calif., Feb. 4, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the addition of David Szekeres to its executive management team as Chief Business Officer and General Counsel. Most recently, Mr. Szekeres served as Deputy General Counsel, Chief M&A Counsel...

2014-02-03 16:25:26

LA JOLLA, Calif., Feb. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 16(th) Annual BIO CEO & Investor Conference being held at the Waldorf-Astoria Hotel in New York City on Tuesday, February 11, 2014 at 11:30 am EST. Dr....

2014-01-13 08:27:16

-Regulus microMarkers(TM) Designed to Support Regulus' Therapeutic Pipeline, its Collaborators and Strategic Partners- LA JOLLA, Calif., Jan. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has established Regulus microMarkers(TM), a new research and development division of Regulus designed to support the expansion of its innovative...